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USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE
LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION
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OBJECTIVES: Health authorities are keen to understand the clin-
ical beneﬁts and mortality reduction afforded by HPV vaccina-
tion for cervical cancer. Complex decision models are not always
the most attractive nor the most appropriate means to highlight
these beneﬁts. The objective was to develop a relatively simple
model to explore the population level impact of an HPV16/18
vaccine. METHODS: We developed a Monte Carlo model that
estimated the absolute number of HPV infections, cervical cancer
cases and deaths over the lifetime of a cohort of women. The
model estimated the cancer cases and mortality avoided in 
the presence of vaccination (base-case: 75% vaccine uptake; 
95% lifetime efﬁcacy). RESULTS: Four countries were selected
including Germany, Poland, Mexico and Taiwan. Each country
has unique patterns of cervical cancer incidence, HPV-type 
prevalence and cervical cancer screening programs. The model
predicted 4584, 4642, 4162 and 37,935 cases of cervical cancer
over the lifetime of unvaccinated 10 year-old girls in each 
of Poland, Germany, Taiwan and Mexico, respectively. Vaccina-
tion resulted in a reduction of total cervical cancer cases 
and deaths of 2392 and 1042 respectively in Poland; 2423 and
857 in Germany; 2143 and 930 in Taiwan and 16,780 and 
8381 in Mexico. Sensitivity analyses showed the most critical
factors in maximizing the beneﬁts of vaccination include vaccine
uptake, efﬁcacy, and duration of the protection. CONCLU-
SIONS: Monte Carlo simulation modeling can be a very power-
ful tool in understanding the potential beneﬁts of vaccination
against HPV infection for reducing cervical cancer and speciﬁc
mortality.
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OBJECTIVES: Cefepime (CPM) 2g q8h is FDA-approved for the
empiric treatment of patients with febrile neutropenia. Pharma-
cokinetic-pharmacodynamic (PK-PD) studies have demonstrated
that cephalosporin efﬁcacy is associated with the percent-time
that the free drug concentration exceeds the minimum inhibitory
concentration (free %T > MIC). This study compares the free
%T > MIC achieved by CPM 2g q8h to four alternative cefepime
regimens in an attempt to determine whether antibiotic 
expenditures can be reduced without compromising predicted
efﬁcacy. METHODS: MIC distributions for Enterobacteriaceae,
Pseudomonas aeruginosa, and Acinetobacter baumanii were
extracted from the 2002 Intensive Care Unit Surveillance System
database. A 10,000-subject Monte Carlo simulation was exe-
cuted for each species/regimen pair using published PK parame-
ters and these MIC distributions. Cefepime probabilities of target
attainment (PTA) were determined for PK-PD targets of ≥50, 60,
and 70%T > MIC. PTA for CPM 2g q8h was compared to the
PTA of four alternative regimens. RESULTS: Overall, the 2002
ISS database contained 3543 Enterobacteriaceae (percent sus-
ceptible, 95%), 1260 P. aeruginosa (53%), and 271 A. baumanii
(36%) isolates. All CPM regimens achieved a PTA similar to that
of CPM 2g q8h against Enterobacteriaceae suggesting an oppor-
tunity for cost minimization. In addition, CPM 1g q6h achieved
equivalent or higher PTA than CPM 2g q8h against P. aerugi-
nosa, and A. baumanii suggesting that the former regimen could
be used to achieve similar predicted efﬁcacy at a fraction of the
daily cost (4g/d vs. 6g/d). However, the PTA vs. P. aeruginosa
and A. baumanii was considerably lower for CPM 1g q8h, 1g
q12h, and 2g q12h compared to CPM 2g q8h suggesting that
these regimens may not be suitable alternatives for P. aeruginosa
or A. baumanii. CONCLUSION: PK-PD models with Monte
Carlo simulation demonstrate that cefepime 1g q6h results in
similar predicted efﬁcacy to cefepime 2g q8h despite a reduction
in total daily drug of 2g/d.
PIN23
A REVIEW OF HERD EFFECTS IN THE ECONOMIC
EVALUATION OF CHILDHOOD VACCINATIONS
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OBJECTIVES: Many childhood vaccines not only protect those
directly immunized, but also indirectly prevent infection or
disease in the non-immunized population through herd effects.
Our objectives were to review the methodological approaches of
including indirect beneﬁts of herd effects in economic evaluations
of childhood vaccines and to describe the sensitivity of the cost-
effectiveness results to herd effects. METHODS: An extensive sys-
tematic review of the literature was conducted. The EMBASE,
MEDLINE, Biosis and Current Contents databases were reviewed
from 1995–2005. Two independent researchers reviewed titles
and abstracts of each article. Additional articles referenced in our
primary search were reviewed for further inclusion. Articles
meeting inclusion criteria were blinded. Two independent
researchers then reviewed and extracted data from all included
articles. The quality of each included article was assessed and any
discrepancies were resolved through consensus. RESULTS: Our
primary search resulted in 27 titles being identiﬁed. Four articles
met our inclusion criteria and 23 articles were excluded (7 review
papers, 7 non-economic, 7 did not include herd effects and 2 did
not assess a childhood vaccine). In each economic evaluation, sen-
sitivity analyses demonstrated that the models were highly sensi-
tive to variations in the estimates of herd effects. In reviewing
how herd effects were being captured, various key issues were
noted: 1) the source of herd effects and the generalizability from
one population to another; 2) the association between herd effects
and the vaccine; and 3) implications of a static or dynamic
approach to incorporate indirect beneﬁts. CONCLUSION: The
indirect beneﬁts attributed to herd effects have been documented
for several vaccines. Economic evaluations have been highly 
sensitive to variations in herd effects. Improving the precision of
measured outcomes at-tributed to herd effects in future economic
evaluations will advance research in this ﬁeld and assist in health
policy decision-making.
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OBJECTIVES: Chronic plantar fasciitis (CPF), the most
common cause of plantar heel pain, lacks an optimal treatment
standard. The electromagnetic Epos® Ultra (EPOS) and the elec-
trohydraulic OssaTron® (OSSA) are the only two FDA approved
extracorporeal shock wave therapy (ESWT) devices for CPF.
This assessment will examine the net health outcomes obtained
when using either of these devices in the treatment of CPF in
patients who failed to achieve satisfactory improvement with
initial conservative treatment. METHODS: Medline® MeSH
heading searches of published peer-reviewed clinical literature
identiﬁed all relevant studies that analyzed ESWT for the treat-
ment of CPF dating to 1996. Additionally, conferences of pro-
fessional organizations were searched for appropriate posters
and abstracts. Outcomes measures focused on the ability of the
comparators to reduce pain and the occurrence of adverse events.
RESULTS: Treatment with EPOS demonstrated pain relief as evi-
denced by visual analog scale (VAS) score improvement from
baseline and compared to control. When compared to control
group, VAS score improvement at 3 months post treatment with
ESWT was signiﬁcantly greater (p = 0.0149). When compared
to baseline VAS scores, the improvement seen at 3, 6, and 12
months post treatment was also signiﬁcantly greater (p < 0.05).
Adverse events in patients using EPOS were limited to pain at
the time of application, which resolved after the treatment was
completed. Treatment with OSSA resulted in greater pain relief
than placebo, revealing an improved VAS score of approximately
1.0 to 2.5 points. Minor adverse events appearing in the area
where the shock wave was applied were resolved within six
weeks. Studies also revealed that ESWT as a whole improved
patients’ mobility scores by 38–51% (p = 0.001) compared to
baseline. CONCLUSIONS: The results of this assessment
demonstrate that both EPOS and OSSA are safe and effective
treatments for CPF patients who did not achieve adequate results
with conservative treatment.
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OBJECTIVE: Plantar fasciitis (PF), the most common cause of
plantar heel pain, affects middle-aged individuals and comprises
15% of overall foot-related complaints. Initial treatments for 
PF include non-steroidal anti-inﬂammatory drugs (NSAIDs),
custom foot orthotics and/or corticosteroid injections into the
heel. When symptoms persist beyond six months it is classiﬁed
as chronic PF (CPF); two options for treatment, surgical inter-
vention and extracorporeal shock wave therapy (ESWT), exist.
This analysis will determine the cost-effectiveness of ESWT in
relation to surgery for the treatment of CPF. METHODS: A
Markov model was constructed based on established manage-
ment practices for the treatment of CPF, simulating the distrib-
ution of patients into one of ﬁve health and treatment states.
Cost and probability values used to populate the model were
derived from appropriate Medicare reimbursement values, retail
and average wholesale prices and published peer-reviewed clini-
cal studies. Cost and effectiveness values were accumulated
monthly over a 12 month period, yielding incremental cost-
effectiveness ratios (ICERs) in dollars per quality-adjusted life
year ($/QALY). RESULTS: Model analysis reveals that surgery
has a lower overall cost of treatment ($1912 v. $2862 respec-
tively) and a higher overall effectiveness in comparison to ESWT
(0.6742 v. 0.5750 QALY respectively). Surgery dominates ESWT
due to its lower overall cost of treatment and higher effective-
ness value, resulting in a lower ICER as compared to ESWT
($2836/QALY v. $4977/QALY respectively). CONCLUSION:
Based on the results of this analysis, surgery is a more cost-
effective option than ESWT for the treatment of chronic plantar
fasciitis; however, the ICER of each of these methods fall 
below the commonly accepted willingness-to-pay threshold of
$50,000/QALY commonly used by payers for the adoption of
new technology. Therefore when surgery has failed, or is not an
option, ESWT remains a viable and cost-effective alternative.
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COMPARISON OF HOSPITAL COST WITH DRG
REIMBURSEMENT RATE IN PATIENTS WITH
PERITROCHANTERIC FRACTURE ACCORDING TO SURGICAL
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OBJECTIVES: The aim of the study is to compare the real hos-
pital cost with DRG reimbursement rate according to surgical
methods in patients with peritrochanteric fractures. METHODS:
Reimbursement data of the Hungarian Diagnosis Related
Groups derive from the ﬁnancial database of the National Health
Insurance Fund Administration. The real hospital costs data
were collected at the Traumatology Center of the University of
Pécs in 2003. We calculated the following cost elements: salaries
of the staff, implants, drugs, bandage, hotel (accommodation)
costs. The salaries and accommodation costs were calculeted for
one day from the administrative records of the University. Four
different surgical methods were included: Gamma nailing and
Dinamic Hip Screw (DHS) providing early weight bearing; Ender
nailing and ﬁx angled plate (FAP) osteosynthesis providing
gradual partial weigh bearing. The average Hungarian Forint
(HUF) vale of one DRG cost-weigh was 100,000HUF. The
exchanga rate: 1USD = 230HUF. RESULTS: The average DRG
cost-weights: 2.87 for DHS, Ender nailing and FAP osteosyn-
thesis, and 4.47 for Gamma nailing. The average accommoda-
tion cost was 13,276HUF/patient/day. The average cost of
wages: 19,985HUF/patient/day. Drug cost: 404HUF/day.
Implants: FAP: 21,300HUF; Ender nail: 3780HUF; DHS:
33,400HUF; Gamma nail: 55,400HUF. The number of average
length of stay was: Gamma nailing and DHS: 8 days, Ender
nailing 10 days, FAP osteosynthesis 13 days. Comparing the
DRG reimbursement with the calculated hospital cost we
received the further balance: Gamma nailing: +122,280HUF;
DHS: -15,720HUF; Ender nailing: -45,610HUF; FAP osteosyn-
thesis -171,685HUF. CONCLUSIONS: We can conclude that
DRG reimbursement exceed the real hospital costs in Gamma
nailing. The hospital costs of DHS, Ender nailing and FAP
osteosynthesis are higher than the DRG reimbursement therefore
in these cases the hospital produces a deﬁcite during the treat-
ment of patients.
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